Business Description
Mesoblast Ltd
SIC : 2836
ISIN : US5907171046
Share Class Description:
FRA:LWB1: ADRTotal Employee Number:
81Description
Mesoblast Ltd is an Australian commercial-stage biotechnology company developing and commercializing allogeneic, off-the-shelf cellular medicines for severe inflammatory conditions. Its lead product, Ryoncil (remestemcel-L-rknd), is approved by the FDA for steroid-refractory acute graft-versus-host disease in pediatric patients, and the company is pursuing additional inflammatory indications for it. Mesoblast also develops its rexlemestrocel-L platform for chronic low back pain associated with degenerative disc disease and for chronic heart failure. The company operates as a single segment centered on its allogeneic cellular medicines platform, targeting specialist physicians and hospital-based transplant and cardiology markets. Its revenue model combines product sales of approved therapies with partnership, licensing, and milestone arrangements, alongside research and development activity. Mesoblast is headquartered in Australia and conducts clinical development and commercialization efforts primarily in the United States and other major markets.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.37 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 111.3 | |||||
3-Year EBITDA Growth Rate | 30.1 | |||||
3-Year EPS without NRI Growth Rate | 25 | |||||
3-Year FCF Growth Rate | 26.2 | |||||
3-Year Book Growth Rate | -10.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 53.25 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.51 | |||||
9-Day RSI | 36.35 | |||||
14-Day RSI | 40.52 | |||||
3-1 Month Momentum % | 18.18 | |||||
6-1 Month Momentum % | 13.49 | |||||
12-1 Month Momentum % | 10 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.43 | |||||
Quick Ratio | 2.09 | |||||
Cash Ratio | 0.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.8 | |||||
Shareholder Yield % | 0.07 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -56.36 | |||||
OCF Margin % | -55.67 | |||||
3-Year ROIIC % | 52.02 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
Forward PE Ratio | 181.16 | |||||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
PS Ratio | 16.17 | |||||
PB Ratio | 3.42 | |||||
EV-to-EBIT | -54.7 | |||||
EV-to-Forward-EBIT | -45.12 | |||||
EV-to-EBITDA | -54.7 | |||||
EV-to-Forward-EBITDA | -57.74 | |||||
EV-to-Revenue | 16.84 | |||||
EV-to-Forward-Revenue | 12.59 | |||||
EV-to-FCF | -43.86 | |||||
Earnings Yield (Greenblatt) % | -1.82 | |||||
FCF Yield % | -2.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mesoblast Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 103.096 | ||
| EPS (TTM) (€) | -0.381 | ||
| Beta | -1.3534 | ||
| 3-Year Sharpe Ratio | 0.54 | ||
| 3-Year Sortino Ratio | 2.2 | ||
| Volatility % | 26.62 | ||
| 14-Day RSI | 40.52 | ||
| 14-Day ATR (€) | 0.410066 | ||
| 20-Day SMA (€) | 13.58 | ||
| 12-1 Month Momentum % | 10 | ||
| 52-Week Range (€) | 10.9 - 17 | ||
| Shares Outstanding (Mil) | 129.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mesoblast Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mesoblast Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2027-02-26 17:00 | In 158 days | ||
| Second quarter earnings results for 2027 | 2027-02-26 | In 157 days | ||
| General meeting for 2026 | 2026-11-25 10:30 | In 65 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-27 08:30 | 13.80 (-2.82%) | ||
| Annual report for 2026 | 2026-08-27 | 13.80 (-2.82%) | ||
| Fourth quarter earnings results for 2026 | 2026-08-27 | 13.80 (-2.82%) | ||
| inaugural R&D Day | 2026-04-08 08:00 | 11.90 (+0.00%) | ||
| Second quarter earnings conference call for 2026 | 2026-02-26 17:00 | 13.80 (+3.76%) | ||
| Second quarter earnings results for 2026 | 2026-02-26 | 13.80 (+3.76%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-04 12:00 | 14.70 (+5.76%) |
Show
Entries
Mesoblast Ltd Frequently Asked Questions
What is Mesoblast Ltd(FRA:LWB1)'s stock price today?
The current price of FRA:LWB1 is €12.70. The 52 week high of FRA:LWB1 is €17.00 and 52 week low is €10.90.
When is next earnings date of Mesoblast Ltd(FRA:LWB1)?
The next earnings date of Mesoblast Ltd(FRA:LWB1) is 2027-02-26 Est..
Does Mesoblast Ltd(FRA:LWB1) pay dividends? If so, how much?
Mesoblast Ltd(FRA:LWB1) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers